Early-life exposure to antibiotics (ABX) has been linked to increases in asthma severity and prevalence in both children and laboratory animals. We explored the immunologic mechanisms behind this association using a mouse model of house dust mite (HDM)-induced asthma and early-life ABX exposure.
Mice were exposed to three short courses of ABX following weaning and experimental asthma was thereafter induced. Airway cell counts and differentials; serum immunoglobulin E (IgE); pulmonary function; lung histopathology; pulmonary regulatory T cells (Tregs); and the fecal microbiome were characterized following ABX exposure and induction of experimental asthma.
Asthma severity was increased in mice exposed to ABX, including: airway eosinophilia, airway hyper-reactivity, serum HDM-specific IgE, and lung histopathology. ABX treatment led to sharp reduction in fecal microbiome diversity, including the loss of pro-regulatory organisms such as Lachnospira. Pulmonary Tregs were reduced with ABX treatment, and this reduction was directly proportional to diminished microbiome diversity.
Intermittent exposure to ABX early in life worsened the severity of experimental asthma and reduced pulmonary Tregs; the latter change correlated with decreased microbiome diversity. These data may suggest targets for immunologic or probiotic therapy to counteract the harmful effects of childhood ABX.
Asthma is an inflammatory disease of the airways which manifests as obstructive respiratory symptoms, including cough, dyspnea, and wheeze.1 While multiple subtypes of asthma exist,2 perhaps the most widely recognized is allergic asthma, wherein the airway inflammation arises from an inappropriate immune response to otherwise innocuous environmental allergens.1 In this subtype, there is an imbalance favoring pro-inflammatory responses (e.g., Th2) as opposed to pro-regulatory responses (e.g., regulatory T or B cells).3 The prevalence of the disease has nearly doubled since the 1980s, today affecting nearly 10% of children.4 The sharp increase in prevalence—termed the “asthma epidemic”5—carries significant costs, as asthma is the third leading cause of childhood hospitalization.6 Many factors have been proposed to explain the asthma epidemic, one of which is the role of early childhood exposure to antibiotics (ABX) and their effect on the host microbiome. Over 20 clinical studies have shown that ABX use, particularly in the first year of life, significantly increases the odds of developing asthma later in childhood.3,7,8
Unfortunately, our recognition of this association has advanced much further than our understanding of the mechanisms behind it. Dissecting such mechanisms is complex in humans, leading multiple groups to explore the influence of ABX on experimental asthma in mice. These studies have been unified in their message: ABX exposure worsens experimental asthma and alters the immune response predisposing toward asthma development.9,10,11,12,13
However, comparisons between these studies and human asthma and ABX have important limitations. Several investigations have focused on ABX exposure prior to birth until later in life, a rare treatment regimen.10,12 Others have exposed mice to ABX for prolonged periods of at least 4 weeks,11,13 much longer than a typical childhood ABX course.14 These reports have provided important insights into how ABX exposure may influence the developing immune system and susceptibility to asthma, but establishment of a more clinically relevant model of early childhood ABX exposure would be of great benefit in determining which factors underlie the increased susceptibility to asthma seen in children. In the present study, we hypothesized that exposing laboratory mice to ABX in a manner similar to that of human children (i.e., brief, but repeated, exposures) would increase the severity of house dust mite (HDM)-induced allergic airway disease (AAD) later in life.
C57BL/6J nursing mothers with 3-week-old female pups were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Upon receipt, pups were weaned and ABX treatment initiated. Mice were housed in plastic cages with corncob bedding at UConn Health. Animal rooms were maintained at 22–24 °C with a 12-h light/dark cycle. Chow and water were supplied ad libitum. Work was performed under UConn Health Institutional Animal Care and Use Committee protocol #100983-0717.
The HDM model of AAD was developed by Bracken et al.15 Briefly, mice were lightly anesthetized with vaporous isoflurane and intranasally (i.n.) instilled with 50 µL of phosphate-buffered saline (PBS) containing 25 μg lyophilized HDM extract (equal parts Dermatophagoides pteronyssinus and D. farinae, Greer Laboratories, Lenoir, NC, USA). HDM was administered beginning at 6 weeks of age for five consecutive days, followed by 2 days of rest for five consecutive weeks (Fig. 1a). Control groups received equal volumes of i.n. PBS in a time-matched manner. All mice were sacrificed 72 h following final HDM challenge.
BAL, blood, and tissue (lymph node and lung) collection
To obtain broncho-alveolar lavage (BAL) fluid cells from the mice, they were lavaged in situ at the time of sacrifice with 5 mL of sterile saline in 1 mL aliquots and BAL cells were pelleted at 600 x g for 10 min at 4 °C. Hilar (lung-draining, mediastinal) lymph nodes (HLNs) were removed, mechanically disrupted into single-cell suspensions, and filtered through a 100 µm Nytex screen (ELKO Filtering Co., Miami, FL, USA). For histopathologic assessment, lavaged half lungs (right lung) were removed and fixed with 4% buffered formalin for 72 h.
Manual total nucleated cell counts were obtained using a hemocytometer with nigrosin dye exclusion as a measure of viability. Cytospin preparations of BAL fluid were stained with May–Grünwald and Giemsa for differential cell analysis via light microscopy.
To isolate serum, blood was collected from mice through cardiac puncture at the time of sacrifice and allowed to clot for 30 min. Clotted blood was spun down at 1600 x g for 10 min and serum removed and stored at −80 °C until needed for analysis.
Cells isolated from BAL fluid and HLN were stained with the following antibodies: CD3epsilon (1:200, Tonbo Biosciences, San Diego, CA, USA; Clone 145-2C11; Cat. #35-0031-U100); CD4 (1:200, eBioscience, San Diego, CA, USA; Clone GK1.5; Cat. #47-0041-82); CD8α (1:200, Tonbo Biosciences; Clone 53-6.7; Cat. #80-0081-U100); CD19 (1:200, Tonbo Biosciences; Clone 1D3; Cat. #35-0193-U500); and CD45R/B220 (1:200, Tonbo Biosciences; Clone RA3-6B2; Cat. #75-0452-U025). Samples were stained as previously described with minor modifications.15 Cells were washed in PBS containing 0.2% bovine serum albumin and 0.1% sodium azide. Aliquots containing 105–107 cells were incubated with anti-mouse CD16/CD32 (1:200, Fc Shield, Tonbo Biosciences; Cat. #70-0161-U500) for 15 min. Cells were then incubated with AlexaFluor350 as a viability marker (1:500, Invitrogen/ThermoFisher Scientific, Waltham, MA, USA; Cat. #A10168) and surface antibodies for 30 min at 4 °C. For staining of Foxp3, cells stained with surface markers were fixed and permeablized with Foxp3/Transcription Factor Staining Kit (Tonbo Biosciences; Cat. #TNB-0607-KIT) according to the manufacturer’s instructions and stained with anti-Foxp3 (1:150, Tonbo Biosciences; Cat. #20-5773-U100) for 30 min at 4 °C. Samples were run with corresponding isotype controls on a BD LSR II (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using FlowJo (Tree Star Software, Ashland, OR, USA).
Tissue histology and scoring
Formalin-fixed, paraffin-embedded lungs were sectioned and stained with hematoxylin and eosin (for gross pathology) and periodic acid-Schiff with hematoxylin counterstain (for mucus production). Sections from all four lobes of the right lung were evaluated in their entirety and representative images taken. Pathologic scoring was performed as described previously.15 Five blinded reviewers simultaneously graded the same visual fields on each slide using a multiheaded microscope. For inflammation scores, 0 corresponded to no detectable inflammation; 1 to mild peribronchiolar/perivascular cuffing with inflammatory cells; 2 to significant peribronchiolar/perivascular clustering; and 3 to significant clustering and airway remodeling (e.g., smooth muscle hypertrophy and hyperplasia). For mucus scores, 0 corresponded to no visible mucus; 1 to occasional and punctate mucus staining in the airways; 2 to presence of ring-like mucus structures in <10% of airways; and 3 to presence of ring-like mucus structures in >10% of airways. Half scores were permitted.
Serum immunoglobulin assessment
Serum HDM-specific immunoglobulin E (IgE) enzyme-linked immunosorbent assay was performed as described previously.15 The 96-well Nunc MaxiSorp flat-bottom plates (ThermoFisher Scientific, Waltham, MA, USA) were coated with 10 μg/mL HDM in sodium bicarbonate buffer (pH 9.5) for 48 h at 4 °C. Following coating, plates came to room temperature for 15 min and were washed six times with 0.05% PBS/Tween 20 (PBST) and blocked for 1 h at 37 °C with BD OptEIA Assay Diluent (BD Biosciences, San Diego, CA, USA; Cat. #555213). After washes, serum samples were added in twofold serial dilutions (range 1:20 to 1:2560) and incubated at room temperature for 1.5 h. Plates were washed eight times with PBST and labeled with Biotin-SP-conjugated goat anti-mouse IgE (Southern Biotech, Birmingham, AL, USA; Cat. #1110-08) diluted 1:5000 in blocking buffer for 1 h at room temperature. Plates were then washed six times and incubated with streptavidin horse radish peroxidase (BD Biosciences, San Jose, CA, USA; Cat. #554066) diluted 1:1000 in blocking buffer at room temperature for 30 min. Plates were washed seven times with PBST and incubated with 3,3′,5,5′-tetramethylbenzidine (TMB, KPL, Gaithersburg, MD, USA; Cat. #50-76-01) for 20 min in the dark at room temperature. The reaction was stopped using 1 M phosphoric acid at equal volume to TMB and the plates were read at dual 450–570 nm wavelengths using an iMark Microplate Reader (Bio-Rad Laboratories, Hercules, CA, USA).
Airway hyper-reactivity (AHR) was assessed as previously described with modification.15 Total responses to increasing doses (0–300 mg/mL) of acetyl-β-methacholine chloride (Sigma-Aldrich, St. Louis, MO, USA; Cat. #A2251) were measured by a flexiVent FX1 mechanical ventilator (SCIREQ Scientific Respiratory Equipment, Montreal, QC, Canada). Mice were anesthetized using urethane (Sigma-Aldrich; Cat. #U2500) administered in saline by intraperitoneal (i.p.) injection at 0.8–5.0 g/kg body weight. Once insensitive to toe pinch, respiratory muscles were paralyzed using 500 ng/kg i.p. pancuronium bromide (Sigma-Aldrich; Cat. #P1918) and mice were immediately placed under mechanical ventilation. Airway reactivity was determined by assessing forced oscillatory mechanics every 10 s for 4 min following each methacholine challenge. Electrocardiogram measurements were monitored to ensure viability for the duration of mechanical ventilation.
The ABX treatment schedule was adapted from Nobel et al.16 Mice were exposed to ABX Mix (ABX Mix), a combination of ampicillin (Sigma-Aldrich; Cat. #A0166), metronidazole (Sigma-Aldrich; Cat. #M1547), neomycin (Sigma-Aldrich; Cat. #N6386), and vancomycin (Sigma-Aldrich; Cat. #V1130), each at 1 g/L, in the drinking water or control (untreated) water. ABX-treated water was sterile filtered prior to placement in mouse cages and provided to mice ad libitum. Control water was treated identically to ABX-containing water (including sterile filtering) save for the addition of ABX. ABX exposure occurred for three 4-day periods (Thursday to Sunday), with a 3-day rest between treatments where all animals were supplied untreated water (Fig. 1a). Treatment began immediately after weaning (3weeks old). Following the third ABX treatment (6 weeks old), mice were administered HDM for 5 weeks according to the model described earlier. For one experiment, two groups of animals (naïve, who received untreated water; and ABX-treated, who received ABX-treated water) were sacrificed following ABX-treated or ABX-untreated water exposure (Supplemental Figure S1A).
Microbiome sampling and DNA extraction
The mouse fecal microbiome was sampled by collecting fresh fecal pellets upon defecation using sterile, RNA-/DNA-/RNAse-/DNAse-free microcentrifuge tubes. Collected pellets were immediately placed at −80 °C for storage. DNA was extracted using a PowerSoil DNA Isolation Kit (MoBio Laboratories, Carlsbad, CA, USA; Cat. #12888-100) according to the manufacturer’s protocol with one modification. At step five (bacterial cell disruption), fecal samples were placed in PowerSoil bead tubes and bead-beaten for 5 min using a single-speed (3450 oscillations/min) Mini-Beadbeater-16 (Biospec Products, Bartlesville, OK, USA). Extracted DNA was quantified using a Qubit dsDNA Broad Range Assay Kit (ThermoFisher Scientific; Cat. #Q32853) and a Qubit 2.0 fluorometer (ThermoFisher Scientific; Cat. #Q32866).
16S rRNA amplification and sequencing
Amplicon library preparation, cleaning, and dilution were performed by the Microbial Analysis, Resources, and Services Facility at UConn. The V4 region of the 16s rRNA gene was amplified in triplicate using the dual barcoded primers (515F and 806R) of Caporaso et al.17 (8 bp Golay-barcoded indices on the 3′ end) and Kozich et al.18 (8 bp on the 5′ end). Amplification was performed using 30 ng of DNA and AccuPrime Taq DNA Polymerase (ThermoFisher Scientific; Cat. #12342010). The PCR reaction was as follows: 95 °C for 3.5 min; 30 cycles of 30 s at 95.0 °C, 30 s at 50.0 °C and 90 s at 72.0 °C; and finally 72.0 °C for 10 min. PCR products were pooled, quantified, and visualized using QIAxcel DNA Fast Analysis (Qiagen, Hilden, Germany). PCR products were normalized based on the concentration of DNA from 250–400 bp and pooled using the QIAgility liquid handling robot (Qiagen). Pooled PCR products were cleaned using the Gene Read Size Selection Kit (Qiagen; Cat. #180514) according to the manufacturer’s protocol. Samples were sequenced on an Illumina MiSeq using v3 chemistry (Illumina, San Diego, CA, USA) according to the manufacturer’s instructions. PhiX (5–20%) was added to the run to increase sample complexity. All sequence read data are available in the Sequence Read Archive (BioProject ID PRJNA401190).
Analysis of 16S rRNA sequence data
Sequence data were analyzed using QIIME 184.108.40.206 The analysis pipeline was derived from Nelson et al.20 Samples were demultiplexed and paired-ends joined with a Phred score cutoff of 19. Joined reads were filtered to be between 245 and 260 bp. Chimeric sequences were removed using UCHIME21 and operational taxonomic units (OTUs) picked at 97% similarity using USEARCH622 in an open-reference manner against the GreenGenes May 2013 release.23 Results were subsampled to 10,000 sequences. For depiction of taxonomic tables, only organisms with an abundance of >1% in more than one group or timepoint were represented as distinct bars. All other organisms are represented by the “Other” category. Supplementary File S1 contains the analysis script used. Supplementary File S2 contains the QIIME parameters used for analysis.
Statistical comparisons between two groups were made using the non-parametric Mann–Whitney U test. Comparisons between three or more groups were made using a two-way analysis of variance. Multiple-comparisons between individual groups were made using Sidak’s multiple-comparisons test. Comparisons of serum immunoglobulin levels and AHR were made by comparing the area under the curve (AUC). Tests were performed using Prism 7 (GraphPad Software, La Jolla, CA, USA). Measures of within-sample (α) and between-sample (β) microbe diversity, including Simpson’s diversity index,24 were made using the QIIME software. Principal coordinate analysis (PCoA) of unweighted UniFrac distances25 was performed using QIIME. Biomarker and effect size assessment for taxa were made using LDA Effect Size (LEfSe).26 LEfSe performs linear discriminant analysis (LDA) to estimate effect sizes of biomarkers (i.e., microbial OTUs) and represents these as LDA scores, where a higher score indicates a stronger association between that biomarker and the variable of interest. For all tests, a threshold of p < 0.05 was used to determine statistical significance.
ABX exposure increased the severity of HDM-induced AAD
Mice developed profound airway leukocytosis (Fig. 1b) following HDM exposure, in agreement with previous results,15 and HDM+ABX Mix animals exhibited threefold higher BAL leukocytosis (Fig. 1b) as compared to HDM alone (29.0 × 105 vs. 9.0 × 105 cells, p < 0.01). Leukocyte counts for both groups were several-fold higher than the level seen in naïve mice (dotted line in Fig. 1b). Naïve mice and mice treated with ABX but not exposed to HDM had similar BAL leukocyte counts (Supplemental Figure S1B).
Exposure to HDM resulted in airway eosinophilia (Fig. 1c), with over 20% of BAL leukocytes being eosinophils in HDM-exposed animals. HDM+ABX Mix animals had twofold higher relative eosinophilia as compared to HDM animals (43% vs. 20%, p < 0.01). Similarly, total eosinophil numbers (Fig. 1d) were over fivefold higher in HDM+ABX Mix animals as compared to HDM-exposed animals (14.0 × 105 vs. 2.4 × 105 eosinophils, p < 0.01). Naïve mice and mice treated with ABX but not exposed to HDM did not demonstrate airways eosinophilia, and both were not significantly different from each other (Supplemental Figure S1C, D).
Serum HDM-specific IgE is elevated in mice treated with ABX early in life
A hallmark of allergic asthma and AAD is the appearance of allergen-specific IgE in the serum. In agreement with our previous results, serum HDM-specific IgE appeared following HDM exposure (in naïve animals, it was virtually undetectable15) (Fig. 1e). However, HDM+ABX Mix animals had significantly higher levels of HDM-specific IgE than HDM animals (0.95 vs. 0.50 mean AUC, p < 0.05).
ABX exposure increased the severity of tissue inflammation in the lungs
HDM exposure led to evidence of perivascular and peribronchial inflammation in the lungs (Fig. 2a, b), particularly clusters of inflammatory cells surrounding the airways and vasculature and airway smooth muscle (ASM) hyperplasia and hypertrophy around the small airways. Blinded comparison of the inflammation and ASM remodeling revealed that HDM+ABX Mix mice harbored more severe histopathologic changes than HDM mice (2.5 vs. 1.5 median score, p < 0.01, Fig. 2e). Pathology scores for HDM mice were similar to those noted in our previous description of the model.15 Evaluation of mucus production (Fig. 2c, d) showed no significant differences in mucus scores (Fig. 2f).
AHR was significantly elevated in ABX-treated mice
Exposure to HDM induces ASM remodeling that results in AHR and bronchoconstriction in response to allergens and agents such as the non-selective muscarinic receptor agonist methacholine.15 Experimental assessment of respiratory function using the flexiVent system revealed that HDM+ABX Mix animals had significantly higher increases in total respiratory system resistance (Rrs) in response to methacholine challenge as compared to HDM animals (5.1 vs. 3.8 mean AUC, p < 0.05, Fig. 3).
ABX exposure reduced the diversity of the fecal microbiome
ABX exposure produced marked alterations in the fecal microbial community (Fig. 4). The composition of the community shifted dramatically (Fig. 4a). ABX Mix treatment, as compared to No Treatment, saw greatly diminished phylum Bacteroidetes, particularly order Bacteroidales, and shifted the composition of phylum Firmicutes from primarily class Clostridia, particularly members of order Clostridiales, to primarily members of genus Turcibacter and genus Enterococcus.
Following HDM exposure, animals not treated with ABX (denoted HDM) had similar community composition to No Treatment animals. However, in ABX Mix mice, 5 weeks of HDM treatment (HDM+ABX Mix) witnessed notable changes in the microbial community, including recovery of many “lost” organisms. However, this recovery was not exact. Organisms of phylum Bacteroidetes, lost with ABX exposure, reappeared, but nearly half of these consisted of genus Parabacteroides, an organism almost absent from either No Treatment or HDM animals. Nearly half of the organisms present were of genus Akkermansia, an organism making up <6% of the microbiome in both No Treatment and HDM animals.
PCoA of the unweighted UniFrac distances confirmed these changes (Fig. 4b). No Treatment and HDM animals were virtually indistinguishable by analysis of PC1 and PC2 (which together represented over 50% of the variance among the samples). Both differed considerably from either ABX Mix or HDM+ABX Mix animals along both PC1 (nearly 43% of the variance) and PC2 (over 19% of the variance). ABX Mix and HDM+ABX Mix saw appreciable difference along PC2 only.
In addition to assessment of the microbiome by examining community composition (Fig. 4a), many metrics exist to quantify the overall diversity of the microbiome. Assessment of the α-diversity (within-sample diversity) revealed that the Simpson diversity index was a third higher for HDM as compared to HDM+ABX Mix (0.954 vs. 0.747, p < 0.01, Fig. 4c).
To separate the effects of ABX exposure from HDM exposure on the composition of the microbiome, LEfSe was utilized to identify taxonomic biomarkers linked to ABX treatment (Fig. 5a). The identified taxa lost with ABX treatment (represented by rightward bars) matched those described in Fig. 4 and included several, such as Lachnospiraceae (3rd row) and Clostridium (7th row), with known immunologic activity. Those taxa which increased in proportion with ABX treatment (represented by leftward bars) included organisms, such as genus Enterococcus (last row), with known pathogenic properties. Further analysis to isolate those organisms whose effects were due to HDM and not ABX (Fig. 5b) revealed several organisms, including those with pro-regulatory properties such as genus Blautia (4th row), more represented in HDM-treated animals (leftward bars). However, the absence or near-absence of these organisms in the HDM+ABX Mix exposed animals (Fig. 4b) suggested this effect was likely driven solely by the non-ABX-treated, HDM-exposed animals.
Decreased diversity of the fecal microbiome directly correlates with the proportion of Tregs in the HLN
Our laboratory15,27 and others28,29 have shown that Foxp3+regulatory T cells (Tregs) play a critical role in the control of asthma and allergic disease, including orchestration of disease suppression and the development of tolerance to both inhaled ovalbumin27,30 and HDM15 from within the in the lung-draining lymph node, or HLN. Assessing the frequency of Foxp3+Tregs in the HLN revealed that HDM+Antibiotic Mix mice had significantly lower proportions of Tregs as a percent of total CD4+T Cells than HDM mice (8.9% vs. 11.1%, vs. p < 0.05, Fig. 6a). Plotting the Simpson diversity index against the proportion of Foxp3+Tregs (Fig. 6b) for both HDM and HDM+Antibiotic Mix mice revealed that there was a positive correlation between microbiome diversity and the proportion of Tregs (Spearman's r = 0.7109, p < 0.01). As diversity increased, so too did Treg proportions. While limited by sample size, assessment of the effect of antibiotic exposure alone on Tregs did not demonstrate a difference with ABX treatment in the absence of HDM exposure (Supplemental Figure S2).
In the present study, we demonstrated that brief, repeated exposure to ABX following weaning significantly worsened the severity of subsequent experimental asthma, including airway leukocytosis, serum IgE levels, and airway hyper-reactivity. ABX administration dramatically reduced the diversity of the fecal microbiome, with differences persisting even following five weeks of HDM administration. Tregs, a critical cell population for moderation of the immune response, were reduced in the lung-draining lymph node following ABX administration, and this reduction correlated directly with microbiome diversity. The present study expands previous reports which have identified increased severity of experimental asthma following long-term ABX11,13 or pre-natal and postnatal ABX treatment.10,12 While we are not the first to explore alternatives to commonly used ABX treatment regimens in laboratory mice—Martin Blaser’s group has shown that similar ABX treatment can produce lasting metabolic changes16—the present study provides strong evidence that such ABX exposure also induces lasting alterations in immune function.
Several clinical studies have linked early-life microbiome diversity, both gut31 and environmental,32 to subsequent protection from asthma and allergy development, although others have found no connection.33 One important difference which may explain this discrepancy is the age of children assessed, as the latter report examined children at ages 2 or 3 years,33 while the other two studies evaluated asthma at age 7 years.31,32 Others have noted that daycare is associated with increased wheeze in the toddler years but reduced asthma by age 6 years,34 and at least one study has linked daycare attendance with increased fecal microbiome diversity,35 suggesting that the true effect of increased early-life microbiome diversity may manifest as early disease but later protection.
Our finding that organisms of family Lachnospiraceae were reduced with ABX exposure matches clinical data linking reduction in these organisms to asthma development in children.33 These organisms have been linked to Treg induction in mice, as members of the family Lachnospiraceae fall within the Clostridial clusters known to induce Tregs through fermentation of dietary fiber and production of short-chain fatty acids.36 Their loss may be one of the factors behind the decrease in Tregs observed in our model.
One interesting observation is that the microbiome appeared to shift most dramatically during HDM administration for those animals exposed to ABX. Perhaps the most likely explanation is that these changes reflect post-ABX changes independent of HDM. Studies of the human and laboratory animal microbiome have shown that ABX rapidly induce microbiome changes, but that the microbial community does not remain fixed once antibiotics are withdrawn.37 It is plausible that the same is happening to the animals in the present study. A second possibility, and one not necessarily mutually exclusive with the first, is that HDM itself is influencing the microbiome to a greater degree in ABX-treated mice. It may be that the inflammation induced by HDM in the lungs leads to systemic alterations in mucosal and epithelial barriers, including in the gut, and that the ABX-depleted microbiome is simply more susceptible to these influences due to its lower diversity and likely lower bacterial burden. Additionally, it is likely that some of the inhaled HDM is eventually expelled from the lung by the action of the pulmonary mucociliary system and swallowed, where the HDM, which contains proteinases and microbial products which may potentially impact the gut microbiome, could conceivably cause greater microbiome changes in the disrupted gut microbiome of ABX-treated mice than those not treated with ABX.
The present study may also provide insight into the struggle to translate experimental benefits of probiotics into human therapies. Despite abundant experimental evidence of asthma protection from probiotics (reviewed in Ref. 3), multiple clinical trials have failed to demonstrate such benefit in humans.38 As our data suggest that overall diversity is associated with Tregs, it may be that administration of one or even a few organisms is insufficient in humans to provide meaningful protection. More comprehensive therapy, such as fecal microbiome transplantation (FMT), may be required to overcome the loss of diversity seen with ABX administration. Indeed, some have suggested that childhood ABX courses should be accompanied by FMT in pill form to counteract the disruption of the microbiome.39
One limitation of the present study is the choice of the ABX cocktail. While based in part on another group’s cocktail of five ABX,11 the fact remains that the present study’s combination is unlikely to be utilized clinically. However, it does provide a means to assess the effect of significant antibiotic disturbance of the microbiome without resorting to germ-free mice and the many complications therein. An important avenue for future investigation would be to determine if a subset of this cocktail was sufficient to increase disease severity (e.g., vancomycin alone or neomycin and metronidazole together). While the composition is not ideal, the use of a series of three short doses rather than the typical pre-natal dosing or weeks or more of postnatal dosing is closer to clinical reality. It will be important to complement existing work evaluating one or multiple ABX prior to birth or for an extended period following birth with future studies evaluating treatment regimens in the pulsed manner of the present study. However, results identified in asthma should be applied with caution to other diseases, as there is some evidence that modulation of disease severity by ABX can depend as much on the disease as the ABX.10,40
A final limitation of the present study concerns the source of the immunologic disturbances seen with ABX therapy. While we have shown that the microbiome is disrupted by ABX therapy, the present study does not conclusively establish that the immunologic changes seen are exclusively derived from disruption of the microbiome. Some ABX, with macrolides being perhaps the classic example, have been recognized to have immunomodulatory properties.41 It is conceivable that the immunologic disturbances we have reported arise as much from the impact of ABX on the host as on the microbiome, although our conclusion is suggested by the body of evidence showing that disruption of the microbiome specifically disturbs the host immune system. A more conclusive assessment could be made using fecal microbiota transplantation to counter the impact of antibiotics, and such work should be the subject of future studies which build on the present one.
To conclude, the present study describes a model of brief, early-life ABX exposure on the subsequent severity of experimental asthma. Exposure to ABX increased the severity of all parameters of experimental asthma, an increase accompanied by a loss of Tregs, known allergic inflammatory modulators, which correlated with a loss of diversity of the fecal microbiome. These data suggest a mechanism for clinical studies that have linked early-life microbiome diversity with subsequent asthma development in children.
Fanta, C. H. Asthma. N. Engl. J. Med. 360, 1002–1014 (2009).
Lötvall, J. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127, 355–360 (2011).
Adami, A. J. & Bracken, S. J. Breathing better through bugs: asthma and the microbiome. Yale J. Biol. Med. 89, 309–324 (2016).
Sears, M. R. Trends in the prevalence of asthma. Chest 145, 219–225 (2014).
Eder, W., Ege, M. J. & von Mutius, E. The asthma epidemic. N. Engl. J. Med. 355, 2226–2235 (2006).
National Center for Health Statistics. Health, United States, 2014: With Special Feature on Adults Aged 55–64 [Internet]. (Centers for Disease Control, Hyattsville, 2015). http://www.cdc.gov/nchs/hus.htm
Yamamoto-Hanada, K., Yang, L., Narita, M., Saito, H. & Ohya, Y. Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5. Ann. Allergy Asthma Immunol. 119, 54–58 (2017).
Walker, W. A. The importance of appropriate initial bacterial colonization of the intestine in newborn, child, and adult health. Pediatr. Res. 82, 387–395 (2017).
Noverr, M. C., Noggle, R. M., Toews, G. B. & Huffnagle, G. B. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect. Immun. 72, 4996–5003 (2004).
Russell, S. L. et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 13, 440–447 (2012).
Hill, D. A. et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat. Med. 18, 538–546 (2012).
Russell, S. L. et al. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. Gut Microbes 4, 158–164 (2013).
Zaiss, M. M. et al. The intestinal microbiota contributes to the ability of helminths to modulate allergic inflammation. Immunity 43, 998–1010 (2015).
Little, P. et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 322, 336–342 (2001).
Bracken, S. J. et al. Long-term exposure to house dust mite leads to the suppression of allergic airway disease despite persistent lung inflammation. Int Arch. Allergy Immunol. 166, 243–258 (2015).
Nobel, Y. R. et al. Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat. Commun. 6, 7486 (2015).
Caporaso, J. G. et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 6, 1621–1624 (2012).
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl. Environ. Microbiol 79, 5112–5120 (2013).
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
Nelson, M. C., Morrison, H. G., Benjamino, J., Grim, S. L. & Graf, J. Analysis, optimization and verification of Illumina-generated 16S rRNA gene amplicon surveys. PLoS ONE 9, e94249 (2014).
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194–2200 (2011).
Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 6, 610–618 (2012).
Simpson, E. H. Measurement of diversity. Nature 163, 688 (1949).
Lozupone, C. & Knight, R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol. 71, 8228–8235 (2005).
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
Carson, W. F. IV et al. Accumulation of regulatory T cells in local draining lymph nodes of the lung correlates with spontaneous resolution of chronic asthma in a murine model. Int Arch. Allergy Immunol. 145, 231–243 (2008).
Taylor, A., Verhagen, J., Akdis, C. A. & Akdis, M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch. Allergy Immunol. 135, 73–82 (2004).
Robinson, D. S. Regulatory T cells and asthma. Clin. Exp. Allergy 39, 1314–1323 (2009).
Natarajan, P. et al. Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-β, and co-localize with CD4+Foxp3+T cells. Mucosal Immunol. 5, 691–701 (2012).
Abrahamsson, T. R. et al. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin. Exp. Allergy 44, 842–850 (2014).
Dannemiller, K. C. et al. Next-generation DNA sequencing reveals that low fungal diversity in house dust is associated with childhood asthma development. Indoor Air 24, 236–247 (2014).
Arrieta, M.-C. et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152 (2015).
Ball, T. M. et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N. Engl. J. Med. 343, 538–543 (2000).
Thompson, A. L., Monteagudo-Mera, A., Cadenas, M. B., Lampl, M. L. & Azcarate-Peril, M. A. Milk- and solid-feeding practices and daycare attendance are associated with differences in bacterial diversity, predominant communities, and metabolic and immune function of the infant gut microbiome. Front. Cell. Infect. Microbiol. 5, 3 (2015).
Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
Koenig, J. E. et al. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA 108(Suppl. 1), 4578–4585 (2011).
Elazab, N. et al. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. Pediatrics 132, e666–e676 (2013).
Blaser, M. J. Antibiotic use and its consequences for the normal microbiome. Science 352, 544–545 (2016).
Russell, S. L. et al. Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases. J. Allergy Clin. Immunol. 135, 100–109 (2015).
Labro, M. T. & Abdelghaffar, H. Immunomodulation by macrolide antibiotics. J. Chemother. (Florence, Italy) 13, 3–8 (2001).
We thank Jacqui Benjamino, Susan Janton, and Michael Nelson of the Graf Lab (UConn Storrs) for feedback and assistance. We also thank David Benson (UConn Storrs) for use of his laboratory space for experimentation. This work was supported by National Institutes of Health grants R01-AI43573 (R.S.T. and C.M.S.), F30-HL122018 (S.J.B.), and F30 HL-126324 (A.J.A.).
The authors declare no competing interests.
Category of Study: Translational
About this article
Cite this article
Adami, A.J., Bracken, S.J., Guernsey, L.A. et al. Early-life antibiotics attenuate regulatory T cell generation and increase the severity of murine house dust mite-induced asthma. Pediatr Res 84, 426–434 (2018). https://doi.org/10.1038/s41390-018-0031-y
Frontiers in Immunology (2020)
Frontiers in Immunology (2020)
Journal of Immunology Research (2020)
Seminars in Immunopathology (2020)
Current Opinion in Allergy and Clinical Immunology (2020)